ICN adds to diagnostics business:
This article was originally published in Clinica
ICN Pharmaceuticals is to acquire 40% of SeaLite Sciences, a private developer of hormonal diagnostic tests. Under the agreement, for which financial terms were not disclosed, ICN will produce and distribute SeaLite's products, including the AquaLite TSH test to detect thyroid disorders. US clearance was recently received for AquaLite and three other fertility kits. ICN will also distribute SeaLite's line of six research products. ICN, which will obtain two seats on SeaLite's board, will have the option to acquire the remaining 60% of the diagnostics company.
You may also be interested in...
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.